-
Jiangsu Vcare Pharma Partners with Geneseeq Technology to Develop Companion Diagnostic for NTRK Inhibitor
•
Jiangsu Vcare PharmaTech Co., Ltd, a biopharmaceutical company based in China, has entered into a partnership with Sino-Canadian firm Geneseeq Technology Inc. The collaboration aims to jointly develop and commercialize a companion diagnostic (CDx) reagent for Vcare’s NTRK inhibitor VC004. Financial details of the agreement were not disclosed. Preliminary clinical…
-
Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist
•
Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its vicagrel, a P2Y12 receptor antagonist. The drug is proposed for the treatment of acute coronary syndrome (ACS), ischemic stroke, and thrombotic cardiovascular and diagnosed…
